Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient‐Level Meta‐Analysis From COMBINE AF
Authors:
- Linda S. JohnsonLJLinda S. Johnson
- Alexander P. BenzABAlexander P. Benz
- Ashkan ShoamaneshASAshkan Shoamanesh
- John W. EikelboomJEJohn W. Eikelboom
- Michael EzekowitzMEMichael Ezekowitz
- Robert P. GiuglianoRGRobert P. Giugliano
- Lars WallentinLWLars Wallentin
- Christian T. RuffCRChristian T. Ruff
- Renato D. LopesRLRenato D. Lopes
- Sanjit JollySJSanjit Jolly
- Richard WhitlockRWRichard Whitlock
- Christopher B. GrangerCGChristopher B. Granger
Open Access
- 3 September 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (17) , e034758
Abstract
Background: Despite oral anticoagulation, patients with atrial fibrillation (AF) remain at risk of ischemic stroke and systemic embolism (SE) events. For patients whose residual risk is sufficiently high, additional therapies might be useful to mitigate stroke risk. Methods and Results: Individual patient data from 5 landmark trials testing oral anticoagulation in AF were pooled in A Collaboration Between Multiple Institutions to Better Investigate Non‐Vitamin K Antagonist Oral Anticoagulant Use in AF (COMBINE AF). We calculated the rate of ischemic stroke/SE among oral anticoagulation–treated patients with a CHA 2 DS 2 ‐VASc score≥2, across strata of CHA 2 DS 2 ‐VASc score, stroke history, and AF type, as either paroxysmal or nonparoxysmal. We included 71 794 patients with AF (median age 72 years, interquartile range, 13 years, 61.3% male) randomized to a direct oral anticoagulant or vitamin K antagonist, and followed for a mean of 2.1 (±0.8) years. The median CHA 2 DS 2 ‐VASc score was 4 (interquartile range, 3–5), 18.8% had a prior stroke, and 76.4% had nonparoxysmal AF. The overall rate of stroke/SE was 1.33%/y (95% CI, 1.27–1.39); 1.38%/y (95% CI, 1.31–1.45) for nonparoxysmal AF, and 1.15%/y (95% CI, 1.05–1.27) for paroxysmal AF. The rate of ischemic stroke/SE increased by a rate ratio of 1.36 (95% CI, 1.32–1.41) per 1‐point increase in CHA 2 DS 2 ‐VASc, reaching 1.67%/y (95% CI, 1.59–1.75) ≥4 CHA 2 DS 2 ‐VASc points. Patients with both nonparoxysmal AF and CHA 2 DS 2 ‐VASc ≥4 had a stroke/SE rate of 1.75%/y (95% CI, 1.66–1.85). In patients with a prior stroke, the risk was 2.51%/y (95% CI, 2.33–2.71). Conclusions: AF type, CHA 2 DS 2 ‐VASc score, and stroke history can identify patients with AF, who despite oral anticoagulation have a residual stroke/SE risk of 1.5% to 2.5% per year. Evaluation of additional stroke/SE prevention strategies in high‐risk patients is warranted.Keywords
This publication has 58 references indexed in Scilit:
- Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 studyAmerican Heart Journal, 2021
- Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and RationaleAmerican Heart Journal, 2021
- Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)American Heart Journal, 2020
- Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial FibrillationAnnals of Neurology, 2020
- Risk of ischemic stroke and utility of CHA2DS2‐VASc score in women and men with atrial fibrillationClinical Cardiology, 2019
- Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settingsJournal of Thrombosis and Thrombolysis, 2019
- Comparison of Clinical Outcomes Among Patients With Atrial Fibrillation or Atrial Flutter Stratified by CHA2DS2-VASc ScoreJAMA Network Open, 2018
- Association of Burden of Atrial Fibrillation With Risk of Ischemic Stroke in Adults With Paroxysmal Atrial FibrillationJAMA Cardiology, 2018
- International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registriesAmerican Heart Journal, 2017
- Validation of Clinical Classification Schemes for Predicting StrokeJAMA, 2001